August 27th 2025
Can you guess the diagnosis?
August 20th 2025
The baby had mild respiratory distress after delivery and briefly required supplemental blow-by oxygen during transitioning.
August 7th 2025
August 6th 2025
In this paper, we provide several cases of human bite injuries, juxtaposed with cases of bite injuries from common animals.
August 4th 2025
Despite their frequency, it can be challenging to distinguish between types of bites. Can you identify the source of this bite mark?
Peter Lio, MD, highlights recent lebrikizumab data to treat atopic dermatitis
Peter Lio, MD, offers thoughts on recent atopic dermatitis data reported for lebrikizumab.
Full case: Linear eruption on the leg of 9-year-old girl
What's the diagnosis of this linear eruption on an adolescent girl's leg?
Poll: What's the diagnosis of this linear eruption on the leg of a 9-year-old girl?
Take your best guess and try to diagnose this 9-year-old girl's linear eruption on the back of her left thigh and leg. Stay tuned for the full case presentation and correct diagnosis!
Baricitinib shows promise for adolescent alopecia areata in phase 3 trial
The study, known as BRAVE-AA-PEDS, was sponsored by Eli Lilly and Company and involved 257 adolescents aged 12 to under 18 years.
Tapinarof cream 1% demonstrates positive long-term results for atopic dermatitis in patients 2 years and up
The newest tapinarof results were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
Lebrikizumab improves atopic dermatitis symptoms in patients previously on dupilumab
Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option.
Weekly review: Roflumilast 0.05% sNDA accepted, palforzia launches for US toddlers
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
FDA accepts roflumilast cream 0.05% sNDA for children with atopic dermatitis
The application is for children aged 2 to 5 years with mild-to-moderate atopic dermatitis.
Roflumilast cream 0.05% demonstrates eczema area severity, itch improvement for pediatric atopic dermatitis
Nearly 40% of children treated with roflumilast cream 0.05% achieved a 75% improvement in EASI-75.
Full case study: Urticarial rash in a 9-hours-old male
On exam, the patient is found to have circular, slightly raised, blanching, erythematous papules on the lower extremities and abdomen.
Puzzler poll: Urticarial rash in a 9-hours-old male
Can you diagnose this patient in our most recent puzzler poll?
Weekly review: Several key FDA approvals, new puzzler case, and more
EN-374 granted rare pediatric disease, orphan drug designations for chronic granulomatous disease
Ensoma's lead program, EN-374, has been granted a pair of FDA designations for the treatment of X-linked chronic granulomatous disease.
A green nail after trauma in an 8-year-old boy
His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit.
Weekly review: New delgocitinib data for eczema, FDA action items, more
FDA grants rezpegaldesleukin fast track to treat moderate, severe atopic dermatitis
The investigational biologic targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells.
Debunking myths about diet and acne
A look into nutrition's role in acne care, highlighted by Colleen Sloan, PA-C, RDN.
Phase 3: Delgocitinib improves chronic hand eczema in adolescents
The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.
Weekly review: Changing atopic dermatology treatments, new puzzler, more
Key atopic dermatitis approvals are changing the treatment landscape
The past year saw a number of approvals adding to the toolbox for atopic dermatitis, including new formulations that work in new mechanisms.
A preview of the January/February 2025 issue of Contemporary Pediatrics
Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the January/February, 2025, issue of Contemporary Pediatrics.
Case study: Boy, aged 10 years, has painful nodules on his feet
Medical advice was sought on the fifth day of symptoms, and by this time, the child was improving clinically.
Can you diagnose this boy with painful nodules on his feet?
The photos in this case were taken soon after the painful and red papules appeared.
Weekly review: Key pediatric dermatology approvals and more
2-week-old girl with lesions on her lips, cheeks, and nasolabial folds
Can you diagnose this healthy, 8.2-lb girl with lesions primarily on her lower lip but also her upper lip, cheeks, and nasolabial folds?
Contemporary Pediatrics’ top 3 FDA approvals of 2024
From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.
Roflumilast 0.05% sNDA submitted to FDA for atopic dermatitis in children 2 to 5 years
Arcutis seeks FDA approval for roflumilast cream 0.05% (ZORVYE) to treat mild to moderate atopic dermatitis in children 2 to 5 years.
FDA approves nemolizumab to treat atopic dermatitis in patients 12 years and up
According to Galderma, approval is based on positive results from the phase 3 ARCADIA clinical trial program.
FDA approves tapinarof cream, 1% for atopic dermatitis patients 2 years and up
"I really hope this becomes a first-line agent that people are comfortable prescribing whether they are in dermatology, pediatric dermatology, or primary care."
Upadacitinib effective in treating atopic dermatitis through 76 weeks
In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).
